Company: HCTI
Filing Date: 2025-11-07
Form Type: PRE 14A
Source: 0001213900-25-107617
Chunk: 10

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-07
Form: PRE 14A
Chunk 10
---
 by us of common stock (or securities convertible into or exercisable for common stock), which alone or together
with sales by our officers, directors or substantial stockholders equals 20% or more of common stock or 20% or more of the voting power
outstanding before the issuance, and (ii)“Minimum Price” means a price that is the lower of: (A) the closing price
(as reflected on NASDAQ.com) immediately preceding the signing of the binding agreement; or (B) the average closing price of common
stock (as reflected on NASDAQ.com) for the five trading days immediately preceding the signing of the binding agreement. Stockholder
approval of this proposal will constitute stockholder approval for purposes of NASDAQ Listing Rule 5635(d).

Furthermore, since the Future Issuances have
not been completed and the specific terms of each Future Issuance is uncertain, Nasdaq will not consider approval by our stockholders
of the Future Issuances to be sufficient for purposes of Nasdaq Rule 5635(d) unless we implement and disclose the following transaction
parameters, which cannot be altered (the “Nasdaq Parameters”):

| 1. | Maximum number of shares of Common Stock Issuable: |

25,000,000

| 2. | Maximum number of shares of Common Stock issuable upon 
 exercise of Warrants:                                  |

50,000,000

| 3. | Maximum Dollar Amount of Issuance: |

$25,000,000.

| 4. | Maximum Amount of discount to the market: |

40%

| 5. | Purpose of the Transaction: |

To provide the Company
with additional working capital.

| 6. | Time frame to complete the offering of Series A Preferred 
 Stock:                                                    |

The closing date is no later than February [●], 2026 (3 months after the Special Meeting)

If the Nasdaq Approval Proposal is approved by
the shareholders at the Special Meeting and we complete Future Issuances under the Nasdaq Parameters, such issuances will not affect
the rights of our existing shareholders, but such issuances will have a dilutive effect on our existing stockholders, including, over
time, the voting power of the existing stockholders.

Recommendation of our Board

<div align='center'>OUR BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE NASDAQ APPROVAL PROPOSAL.

5

SECURITY OWNERSHIP OF CERTAIN BENEF